Clarus Ventures Backs Neomend

Xconomy Boston — 

Clarus Ventures, a Cambridge, MA-based venture fund, has invested $17 million in the surgical hydrogel developer Neomend, as part of the Irvine, CA-based company’s $30 million Series D funding round. Neomend, which develops its hydrogels to seal surgical wounds, also attracted investments in the round from Novo Ventures, Prospect Venture Partners, Sanderling Ventures, and Vivo Ventures, according to the company’s press release.